Imago BioSciences to Present Updated Data from Phase 2 Studies of Bomedemstat for the Treatment of Essential Thrombocythemia and Myelofibrosis at 2021 European Hematology Association Virtual Congress

May 21, 2021 15:58 UTC

 

 
 

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Imago Biosciences, Inc. (“Imago”), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that updated Phase 2 data from its two clinical programs for bomedemstat (IMG-7289) will be highlighted in e-poster presentations at the European Hematology Association (EHA) 2021 Virtual Congress, held online June 9 – 17, 2021.

2021 EHA Virtual Congress Presentation Information

Title: A Phase 2 Study of the LSD1 Inhibitor IMG-7289 (Bomedemstat) for the Treatment of Essential Thrombocythemia
Session Title: Myeloproliferative neoplasms - Clinical
Abstract: EHA-2504

Title: A Phase 2 Study of the LSD1 Inhibitor IMG-7289 (Bomedemstat) for the Treatment of Advanced Myelofibrosis
Session Title: Myeloproliferative neoplasms - Clinical
Abstract: EHA-2787

The abstracts are available on the EHA Annual Congress website at www.ehaweb.org/congress. All e-poster presentations will be made available on the EHA website for on-demand viewing on June 11, 2021.

About Imago BioSciences

Imago BioSciences is a clinical-stage biopharmaceutical company discovering and developing novel small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. Imago is focused on improving the quality of life of patients with cancer and bone marrow diseases in addition to prolonging their lives. Bomedemstat, an orally available, small molecule inhibitor of LSD1, is the lead product candidate discovered by Imago for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow. Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment essential thrombocythemia (ET) and myelofibrosis (MF). Bomedemstat has U.S. FDA Orphan Drug and Fast Track Designation for the treatment of ET and MF, Orphan Drug Designation for treatment of AML, and PRIME designation by the European Medicines Agency for the treatment of MF. Imago is backed by leading private, crossover and strategic investors including a fund managed by Blackstone Life Sciences, Frazier Healthcare Partners, Omega Funds, Farallon Capital Management, L.L.C., funds and accounts advised by T. Rowe Price Associates, Inc., and funds and accounts managed by Blackrock Advisors, LLC. The company is based in South San Francisco, California. To learn more, visit www.imagobio.com, www.myelofibrosisclinicalstudy.com, www.etclinicalstudy.com and follow us on Twitter @ImagoBioRx, Facebook, LinkedIn and YouTube.

Contacts

Media Contact:
Will Zasadny
Canale Communications
will.zasadny@canalecomm.com

Company Contact:
Matthew Plunkett, PhD
Chief Financial Officer, Imago Biosciences
matthew.plunkett@imagobio.com

 
 

Source: Imago BioSciences, Inc.

Back to news